Hedi Ben Brahim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSylvie berrebiTransgene euronextAlessandro rivaLucie larguierBen brahimCorporate communicationsIchnos sciencesCompany board of directorsLife sciencesAffairs at novartis pharmaceuticalsCompensation committeeGlobal head of oncology developmentUniversity of milanCell gene therapy at gilead sciences

Transgene : Inside Information / Other news releases

PRESS RELEASE Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio . | May 5, 2023

United statesUnited kingdomTransgene euronextAlessandro rivaBen brahimSylvie berrebiLucie larguierLife sciencesIchnos sciencesCell gene therapy at gilead sciencesUniversity of milanCompany board of directorsCorporate communicationsCompensation committeeAffairs at novartis pharmaceuticalsGlobal head of oncology development

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of

United statesUnited kingdomLucie larguierChristophe le tourneauLe tourneauBen brahimTransgene euronextSylvie berrebi george underwoodMaud brandelyHead of the department drug developmentData monitoring committeeCurie instituteMerck kgaPfizer incCorporate communicationsMerck kgaa

Positive Readouts for Transgene s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022

TG4001- Results from the interim analysis of the randomized Phase II trial in HPV-positive anogenital cancers to be released in Q4 2022 TG4050 (myvac platform) - New positive Phase I data presented

United statesUnited kingdomLucie larguierLaurence espinasseTransgene euronextBen brahimAlessandro rivaSylvie berrebiCongress onCorporate communicationsLife sciencesMerck coEuronext parisHedi ben brahimNon executive chairmanJean yves blay

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Strasbourg, France, and Lund, Sweden, June 28, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on th.

United statesBen brahimMerck co incBioinvent international ab nasdaq stockholmEuronext parisBioinvent internationalNasdaq stockholmHedi ben brahim